Journal Cover
JAMA The Journal of the American Medical Association
Journal Prestige (SJR): 8.876
Citation Impact (citeScore): 7
Number of Followers: 2062  
 
  Full-text available via subscription Subscription journal
ISSN (Print) 0098-7484 - ISSN (Online) 1538-3598
Published by American Medical Association Homepage  [14 journals]
  • Highlights for August 20, 2019
    • Pages: 589 - 591
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2018.15465
      Issue No: Vol. 322, No. 7 (2019)
       
  • JAMA
    • Pages: 593 - 594
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2018.15466
      Issue No: Vol. 322, No. 7 (2019)
       
  • Weighing the Risks and Rewards of Peanut Oral Immunotherapy
    • Authors: Abbasi J.
      Pages: 596 - 598
      Abstract: This Medical News article discusses a recent meta-analysis of oral immunotherapy trials for people with peanut allergies.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.9142
      Issue No: Vol. 322, No. 7 (2019)
       
  • Getting Social: Physicians Can Counteract Misinformation With an Online
           Presence
    • Authors: Rubin R.
      Pages: 598 - 600
      Abstract: This Medical News interview discusses the value of social media for health care.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.10779
      Issue No: Vol. 322, No. 7 (2019)
       
  • Averting Alert Fatigue to Prevent Adverse Drug Reactions
    • Authors: Carroll AE.
      Pages: 601 - 601
      Abstract: Although various electronic health records (EHRs) have different features, nearly all seem to have alerts for potential problems with drug prescribing. It’s one thing that many believe that EHRs do very well. However, a recent study warns that when it comes to opioids and benzodiazepines, we shouldn’t always assume that such alerts work as intended.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.11710
      Issue No: Vol. 322, No. 7 (2019)
       
  • Prevalence and Treatment of Chronic Obstructive Pulmonary Disease (COPD)
           in the United States
    • Authors: Biener AI; Decker SL, Rohde F.
      Pages: 602 - 602
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.10241
      Issue No: Vol. 322, No. 7 (2019)
       
  • Fighting Epilepsy Stigma
    • Authors: Kuehn B.
      Pages: 603 - 603
      Abstract: Greater efforts are needed worldwide to combat stigma and discrimination against patients with epilepsy, according to a World Health Organization report.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.11802
      Issue No: Vol. 322, No. 7 (2019)
       
  • Viruses Drive Children’s Pneumonia
    • Authors: Kuehn B.
      Pages: 603 - 603
      Abstract: Respiratory syncytial virus and other viruses have replaced bacteria as the leading cause of severe childhood pneumonia in low- and middle-income countries, according to a study in The Lancet that examined childhood pneumonia in 7 Asian and African countries.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.11801
      Issue No: Vol. 322, No. 7 (2019)
       
  • Gag Rule May Increase Abortions
    • Authors: Kuehn B.
      Pages: 603 - 603
      Abstract: Abortion rates in some sub-Saharan African countries increased by 40% when a US policy that pulled federal funding from overseas organizations that performed or discussed abortion was in effect, according to a study in The Lancet Global Health.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.11062
      Issue No: Vol. 322, No. 7 (2019)
       
  • First Treatment for Rare Autoimmune Neuromyelitis
    • Authors: Sancar F.
      Pages: 604 - 604
      Abstract: The humanized monocolonal antibody eculizumab has been approved for adults with neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory condition of the central nervous system (CNS). The disorder causes recurrent optic neuritis and myelitis, which may lead to permanent vision loss and paralysis.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.11804
      Issue No: Vol. 322, No. 7 (2019)
       
  • Ventilator Recall
    • Authors: Sancar F.
      Pages: 604 - 604
      Abstract: More than 4000 Hamilton-G5 ventilators have been recalled due to a sporadic error message that can cause it to stop working, the FDA recently announced. The device provides breathing support for adult, pediatric, infant, and neonatal patients in intensive care.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.11803
      Issue No: Vol. 322, No. 7 (2019)
       
  • Another Option for Hypoactive Sexual Desire
    • Authors: Sancar F.
      Pages: 604 - 604
      Abstract: The FDA recently approved bremelanotide for acquired generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It’s the first “as-needed” treatment for HSDD, a common condition characterized by low libido that causes distress or interpersonal difficulty and isn’t attributed to a coexisting medical or psychiatric condition, relationship problems, or medications.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.11515
      Issue No: Vol. 322, No. 7 (2019)
       
  • Implications of the United States Medical Licensing Examination (USMLE)
           Score Reporting Structure
    • Authors: Swails JL; Aibana O, Stoll BJ.
      Pages: 605 - 606
      Abstract: In the context of joint preliminary recommendations from the Federation of State Medical Boards and the National Board of Medical Examiners to consider moving the USMLE examination to pass-fail score reporting, this Viewpoint discusses how the current 3-digit score reporting structure is used by residency program directors and medical schools, how it may distract students from developing qualities of innovation and humanism important to medicine, and how it may facilitate workforce underrepresentation of some student groups.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.9669
      Issue No: Vol. 322, No. 7 (2019)
       
  • The 2019 Supreme Court Ruling on Merck‚Äôs Liability for
           Bisphosphonate-Related Atypical Femoral Fractures
    • Authors: Johnston MC; Boumil MM, Curfman G.
      Pages: 607 - 608
      Abstract: In May 2019 the US Supreme Court sent back to lower courts the question of whether Merck Sharpe & Dohme Corp was liable for atypical fractures from its osteoporosis drug alendronate because it did not identify the adverse effect in the product’s label. This Viewpoint discusses the legal questions of liability raised by the case and the implication of the decision for the pharmaceutical industry and for patients alleging harmed from prescription drugs.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.8515
      Issue No: Vol. 322, No. 7 (2019)
       
  • Protecting Pregnant Women With Opioid and Substance Use Disorders
           Participating in Research
    • Authors: Davis JM; Yao L, Bierer BE.
      Pages: 609 - 610
      Abstract: This Viewpoint discusses the potential risks faced by pregnant women with substance use disorders who participate in clinical research, including criminal prosecution for drug use while pregnant and custody loss of their children, and proposes changes to research procedures and disclosure provisions to encourage their participation so the evidence base informing their care and addressing the opioid epidemic more generally can advance.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.9002
      Issue No: Vol. 322, No. 7 (2019)
       
  • Electronic Fetal Monitoring to Prevent Fetal Brain Injury—Ubiquitous
           But Flawed
    • Authors: Hirsch E.
      Pages: 611 - 612
      Abstract: This Viewpoint argues that the near-universal adoption of electronic fetal monitoring (EFM) in labor and delivery units has occurred without evidence that it has reduced adverse neurological events and has contributed to an increase in US cesarean delivery rates, and calls for the education of physicians and the public about EFM’s demonstrated reliability and value.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.8918
      Issue No: Vol. 322, No. 7 (2019)
       
  • A Tale of Two Lungs: Helping Patients Make Decisions
    • Authors: Hensley MK.
      Pages: 613 - 614
      Abstract: In this narrative medicine essay, a critical care physician works through lessons he learned from his experience with a man with end-stage lung disease going into terminal respiratory failure who consented to intubation only if he had a chance for a lung transplant and considers how to balance patient autonomy with medical paternalism when good outcomes are unlikely and the best decisions are uncertain.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.11287
      Issue No: Vol. 322, No. 7 (2019)
       
  • Maintenance Treatment for Psychotic Depressive Disorders
    • Authors: Coryell WH.
      Pages: 615 - 617
      Abstract: Psychotic features, such as delusions of guilt or persecution, in major depressive disorder (MDD) attracted little research interest before the observation that patients with psychotic depression responded poorly to tricyclic antidepressants. Subsequent work showed that other depressive symptoms, particularly those of the melancholic subtype, are substantially more severe in this condition than they are in MDD without psychotic features. Second only to those with catatonic features, patients with psychotic features are most likely to experience hyperactivity of the hypothalamic-pituitary-adrenal axis and are much less likely than those without psychotic features to respond to placebo or to hospitalization alone.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.9682
      Issue No: Vol. 322, No. 7 (2019)
       
  • Thyroid Function Test Abnormalities During Pregnancy
    • Authors: Cappola AR; Casey BM.
      Pages: 617 - 619
      Abstract: Thyroid hormones affect the growth, metabolism, and function of multiple organs in the body. If adaptive mechanisms were not in place during pregnancy, physiological increases in the quantity of circulating thyroid hormone–binding proteins would result in lower concentrations of unbound (free) thyroid hormones and subsequent adverse maternal and fetal consequences. Fortunately, the hypothalamic-pituitary-thyroid axis compensates, matching thyroidal output to maternal requirements, and, as long as the thyroid has adequate reserves, thyrotropin (often referred to as thyroid-stimulating hormone or TSH) and free thyroxine are maintained at normal concentrations.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.10159
      Issue No: Vol. 322, No. 7 (2019)
       
  • Broadening Criteria for BRCA1/2 Evaluation
    • Authors: Domchek S; Robson M.
      Pages: 619 - 621
      Abstract: Pathogenic variants (ie, mutations) in the breast cancer susceptibility 1 and 2 (BRCA1/2) genes are associated with a high risk of ovarian and female breast cancer as well as, particularly for BRCA2, elevated risks of male breast cancer, aggressive prostate cancer, and pancreatic cancer. The risks of ovarian cancer and breast cancer are as high as 45% and 70%, respectively. The detection of a BRCA1/2 pathogenic variant can significantly alter medical management (by early detection or risk reduction strategies) and improve outcomes.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.9688
      Issue No: Vol. 322, No. 7 (2019)
       
  • Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With
           Psychotic Depression in Remission
    • Authors: Flint AJ; Meyers BS, Rothschild AJ, et al.
      Pages: 622 - 631
      Abstract: This randomized clinical trial compares the effect on relapse of continuing olanzapine vs placebo among patients with psychotic depression who achieved remission of psychosis and depressive symptoms while taking olanzapine and sertraline.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.10517
      Issue No: Vol. 322, No. 7 (2019)
       
  • Association of Thyroid Function Test Abnormalities and Thyroid
           Autoimmunity With Preterm Birth
    • Pages: 632 - 641
      Abstract: This individual participant data meta-analysis pooled data from 19 cohort studies to assess whether maternal thyroid function test abnormalities and thyroid autoimmunity are risk factors for preterm birth among pregnant women without overt thyroid disease.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.10931
      Issue No: Vol. 322, No. 7 (2019)
       
  • Association of Smoking Cessation With Subsequent Risk of Cardiovascular
           Disease
    • Authors: Duncan MS; Freiberg MS, Greevy RA, Jr, et al.
      Pages: 642 - 650
      Abstract: This cohort study uses Framingham Heart Study data to assess the association between years since smoking cessation and incident cardiovascular disease (CVD), compared with current and never smoking, among participants without baseline CVD over a median follow-up of 26 years.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.10298
      Issue No: Vol. 322, No. 7 (2019)
       
  • Smoking Cessation and Reduction of Cardiovascular Disease Risk
    • Authors: Cole TB.
      Pages: 651 - 651
      Abstract: Smoking cessation improves cardiovascular health, but not right away. Studies have come to different conclusions about how long it takes for the excess risk associated with smoking to subside to the level of a never smoker, with estimates varying widely, from 2 to 20 years. The study by Duncan et al, which was based on repeated assessments of tobacco exposure, other risk factors, and cardiovascular disease (CVD) outcomes, provides estimates of cardiovascular risk among former smokers that are likely to be more precise and accurate than those of previous studies. This information is important for clinicians and patients. According to these new analyses, a former smoker’s risk of CVD does not approximate the risk of a never smoker until 10 to 15 years have elapsed since cessation. The risk of CVD does appear to decline substantially within the first 5 years, and smokers who are contemplating quitting may take some encouragement from this finding. On a population level, the implications of this study are sobering: reductions in CVD associated with declining smoking rates in countries such as Japan and the United States can be expected to lag quit rates by 10 to 15 years, and in countries where smoking rates appear to be increasing, such as China and Indonesia, rates of CVD are likely to increase for decades into the future. To counter these trends, all countries, particularly those most vulnerable to tobacco marketing, should implement tobacco control strategies to prevent smoking initiation and motivate current smokers to quit.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.11166
      Issue No: Vol. 322, No. 7 (2019)
       
  • USPSTF Recommendation: Assessment, Counseling, and Testing for BRCA
           -Related Cancer
    • Pages: 652 - 665
      Abstract: This 2019 Recommendation Statement from the US Preventive Services Task Force recommends that women with a family or personal history associated with increased risk for harmful mutations in the BRCA1/2 genes and with a positive result on a brief familial risk assessment tool should receive genetic counseling and, if indicated, genetic testing (B recommendation) and recommends against routine risk assessment, genetic counseling, or genetic testing for women whose personal or family history is not associated with potentially harmful BRCA1/2 gene mutations (D recommendation).
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.10987
      Issue No: Vol. 322, No. 7 (2019)
       
  • USPSTF Report: Risk Assessment, Genetic Counseling, and Testing for BRCA-
           Related Cancer
    • Authors: Nelson HD; Pappas M, Cantor A, et al.
      Pages: 666 - 685
      Abstract: This systematic review to support the 2019 US Preventive Services Task Force Recommendation Statement on risk assessment, genetic counseling, and genetic testing for BRCA-related cancer summarizes published evidence on the benefits and harms of assessment, counseling, and testing in women without recently diagnosed BRCA1/2-related cancer.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.8430
      Issue No: Vol. 322, No. 7 (2019)
       
  • Catheter Ablation for Atrial Fibrillation in 2019
    • Authors: Upadhyay GA; Alenghat FJ.
      Pages: 686 - 687
      Abstract: This JAMA Insights Clinical Update reviews management approaches to atrial fibrillation (AF), including assessment of the need for anticoagulation, and controversies over the need for rhythm control and the role of catheter ablation for maintaining sinus rhythm and reducing AF-associated symptoms.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.10929
      Issue No: Vol. 322, No. 7 (2019)
       
  • ECG Diagnosis of Atrial Arrythmias
    • Authors: Soliman EZ; Bhave PD, Chen LY.
      Pages: 688 - 689
      Abstract: This Clinical Challenge reviews ways to distinguish atrial ectopy, AV block, multifocal atrial tachycardia, and other supraventricular tachycardias from atrial fibrillation in patients with absent P waves, irregularly irregular R-R intervals, and f waves on electrocardiography.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.10925
      Issue No: Vol. 322, No. 7 (2019)
       
  • Prevalence and Characteristics of Virginia Hospitals Suing Patients and
           Garnishing Wages for Unpaid Bills
    • Authors: Bruhn WE; Rutkow L, Wang P, et al.
      Pages: 691 - 692
      Abstract: This study uses 2017 court records to characterize how frequently Virginia hospitals take legal action to garnish patients’ wages to recover unpaid medical expenses, and the characteristics of hospitals and patient employers associated with the actions.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.9144
      Issue No: Vol. 322, No. 7 (2019)
       
  • Monitoring Adherence to Inhaled Medications
    • Authors: Bryant GA; Dy-Boarman EA, Kassel LE.
      Pages: 692 - 693
      Abstract: To the Editor Drs Hew and Reddel highlighted the importance of adherence to inhaled controller medications in the treatment of chronic respiratory conditions. Some of their claims regarding adherence monitoring systems for inhalers lacked a balanced perspective.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.8643
      Issue No: Vol. 322, No. 7 (2019)
       
  • Monitoring Adherence to Inhaled Medications—Reply
    • Authors: Hew M; Reddel HK.
      Pages: 693 - 694
      Abstract: In Reply While we agree with the important points that Dr Bryant and colleagues have made about the role of multidisciplinary teams in improving adherence, we believe they may have misinterpreted our main thesis by inadvertently conflating adherence monitoring with adherence management. We have argued that input from pharmaceutical companies is essential to rectify the current lack of adherence monitoring. We do not, however, equate this with delivering overall adherence management, which is a far broader endeavor, needing to take into account multiple contributory factors and requiring an adequately resourced multidisciplinary approach, beyond the remit of any pharmaceutical company.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.8654
      Issue No: Vol. 322, No. 7 (2019)
       
  • Resuming Anticoagulation After Cerebral Intraparenchymal
           Hemorrhage—Reply
    • Authors: Gross BA; Jankowitz BT, Friedlander RM.
      Pages: 694 - 695
      Abstract: In Reply We agree with Ms Leasure and Dr Sheth that there is no firm evidence to support timing of restarting anticoagulation therapy following IPH, particularly for new-generation anticoagulants. We stated in our review that restarting anticoagulation therapy should be delayed by 1 to 2 months in patients with nonlobar IPH unrelated to amyloid angiopathy, but we did not state that anticoagulation therapy must be restarted in all cases at this time. In patients with a correctable etiologic cause of IPH and stronger indications for anticoagulation therapy, such as mechanical heart valves, anticoagulation therapy may need to be restarted even sooner. As Leasure and Sheth acknowledge, we summarized the available evidence to date, including a meta-analysis reinforcing the intuitive reduction of thromboembolic complications in patients resuming anticoagulation therapy. We agree that results of forthcoming trials will prove particularly useful in providing more rigorous evidence for future guidelines.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.8658
      Issue No: Vol. 322, No. 7 (2019)
       
  • Resuming Anticoagulation After Cerebral Intraparenchymal Hemorrhage
    • Authors: Leasure AC; Sheth KN.
      Pages: 694 - 694
      Abstract: To the Editor Dr Gross and colleagues reviewed the management options for cerebral intraparenchymal hemorrhage (IPH) to help guide clinical decision-making. The review captured the most up-to-date evidence for clinical management of IPH; however, the authors’ suggestion to resume oral anticoagulation therapy 1 to 2 months after deep IPH unrelated to cerebral amyloid angiopathy may not be supported by firm evidence. We believe the recommendations should be more cautious. The 2015 American Heart Association guidelines do not provide a definitive recommendation for resumption of anticoagulation therapy after nonlobar IPH. In the absence of results from randomized clinical trials, the safety and optimal timing of restarting oral anticoagulation therapy in patients with IPH remains unknown.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.8650
      Issue No: Vol. 322, No. 7 (2019)
       
  • Treating Hypercholesterolemia in Older Adults—Reply
    • Authors: Skolnik N.
      Pages: 695 - 696
      Abstract: In Reply Dr Forman and colleagues, in a response to my Viewpoint, provide clarification regarding the IIb grade of the recommendation for management of hypercholesterolemia in older adults. A IIb recommendation indicates that a recommendation is based on weak evidence that the benefit is greater than the risk. The fact that clinical judgment should be used in carrying out a IIb recommendation is true but not distinct to IIb recommendations. Clinical judgment needs to be used for all recommendations.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.8807
      Issue No: Vol. 322, No. 7 (2019)
       
  • Treating Hypercholesterolemia in Older Adults
    • Authors: Forman DE; Stone NJ, Grundy SM.
      Pages: 695 - 695
      Abstract: To the Editor In his Viewpoint, Dr Skolnik discussed the 2018 American College of Cardiology (ACC)/American Heart Association (AHA) guideline on the management of blood cholesterol and its implications for older adults. We would like to highlight relevant features of the guidelines that merit greater recognition.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.8803
      Issue No: Vol. 322, No. 7 (2019)
       
  • Numbers of Patients Transposed in Text
    • Pages: 696 - 696
      Abstract: In the Original Investigation entitled “Effect of Pressure Support vs T-Piece Ventilation Strategies During Spontaneous Breathing Trials on Successful Extubation Among Patients Receiving Mechanical Ventilation: A Randomized Clinical Trial,” published in the June 11, 2019, issue of JAMA, patient numbers were transposed in a sentence in the Results section of the text. The first sentence in the Secondary Outcomes subsection on page 2178 should have read “After the first SBT, 532 patients (92.5%) undergoing the 30-minute PSV SBT and 486 patients (84.1%) undergoing the 2-hour T-piece SBT were extubated (difference, 8.4%; 95% CI, 4.7%-12.1%; P < .001).” This article was corrected online.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.11119
      Issue No: Vol. 322, No. 7 (2019)
       
  • Clarification of Reporting of Potential Conflicts of Interest in JAMA
           Articles
    • Authors: Dzau VJ.
      Pages: 696 - 696
      Abstract: To the Editor I am writing to provide additional information to clarify conflict of interest disclosures in articles I published in JAMA in 2014, 2016, and 2019.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.11051
      Issue No: Vol. 322, No. 7 (2019)
       
  • Clarification of Reporting of Potential Conflicts of Interest
    • Pages: 696 - 696
      Abstract: In 3 Viewpoints published in JAMA, additional information was needed to clarify the conflict of interest disclosures. The Conflict of Interest Disclosures statements in 2 of the Viewpoints should have read as follows: “Dr Dzau reports having served previously as a member of the board of Medtronic Inc ending in June 2014 and receiving compensation from that company.” For the third Viewpoint, the disclosure statement should have read as follows: “Dr Dzau reports having served previously as a member of the board of Alnylam Pharmaceuticals ending in June 2014 and receiving compensation from that company.” These articles have been corrected online and a letter of explanation has also been published for further clarification.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.11017
      Issue No: Vol. 322, No. 7 (2019)
       
  • Playing Word Games
    • Authors: Martinello S.
      Pages: 698 - 698
      Abstract: I sprinkle hints, seeds in the withering garden of your brain, hope words will sprout, blossom on your lips. But deep in the gray matter, atrophy spreads like a biblical pestilence. In that un-Eden, hummingbirds dart, like crazed syllables, scatter alphabets like fallen petals amid stems of thought— bare, but pretending to be bright. Colors for flowers, all I could expect.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.5687
      Issue No: Vol. 322, No. 7 (2019)
       
  • The Relation of Pathology to Practice
    • Pages: 699 - 699
      Abstract: With the swinging of the pendulum in the science of medicine has come the fashion of neglecting pathology, the pathology of the type called, in the olden days, morbid anatomy. This neglect is shown in many ways: in a diminution in the volume of published work; in the lessened number of necropsies performed, and in the smaller number of men who are actively interested in the subject. It may be that the great days of Rokitansky, of Virchow and of Cohnheim have passed never to return; but it is more likely that the next swing of the pendulum will bring with it a renewed interest in the study of the anatomic changes which accompany disease.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2018.15473
      Issue No: Vol. 322, No. 7 (2019)
       
  • Testing for BRCA Mutations
    • Authors: Jin J.
      Pages: 702 - 702
      Abstract: This JAMA Patient Page describes the US Preventive Services Task Force’s recently published recommendations on risk assessment and genetic counseling and testing for BRCA mutations and BRCA-related cancers.
      PubDate: Tue, 20 Aug 2019 00:00:00 GMT
      DOI: 10.1001/jama.2019.11251
      Issue No: Vol. 322, No. 7 (2019)
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 3.226.251.81
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-